Imusyn, founded in 2001, is a biotechnology company which specialises in alloproteomics with the objective of advancing allogeneic cellular therapies and personalised medicine. The company’s primary focus is the development and manufacture of recombinant proteins from polymorphic genetic systems including major histocompatibility complex genes, blood group genes and many other immunology related or immunogenetically relevant genes. Using proprietary recombinant protein technology makes a high-yield, massive parallel manufacturing process possible. With these techniques, we can meet the demands of customers on the medical diagnostic and life sciences markets for modern research tools in next-generation drug and diagnostic assay developments.
Company Details
Imusyn Questions
Imusyn's website is imusyn.de
Imusyn's LinkedIn profile is https://de.linkedin.com/company/imusyn
Imusyn has
9 employees.
View email and phone details for 9
employees at Imusyn.
Imusyn's industry is
Biotechnology
Imusyn's top competitors are
Biointelligence Gmbh,
Bbt Biotech Gmbh,
Capricorn Scientific Gmbh,
Biaffin Gmbh & Co Kg,
Allogenetics,
Ceevoy Solutions Gmbh,
Inno-Train Diagnostik,
Koek Biotech Eu Gmbh,
Imugex Gmbh,
Vivo Science Gmbh.
Imusyn's categories are Biotechnology
Imusyn's founding year is 2001
